Evaluation of Colchicine effect on Plasma Level of Cardiac Troponin-I and Creatine Kinase- MB in patients with ischemic heart disease who undergo PCI

Abstract

Background: It has been shown that the elevation of cardiac biomarkers Creatine Kinase-MB (CK-MB) and Cardiac Troponin I (cTnI) following percutaneous coronary Intervention (PCI) significantly linked with mortality and morbidity. Cardioprotection has become one of the important therapeutic concerns during PCI. Colchicines is an anti inflammatory, anti oxidant and anti mitotic agent with cardiovascular benefits. Therefore in this study, we aimed to evaluate the cardioprotective effect of in pre-procedural myocardial injury (PMI) following elective PCI. Aim: Due to the potential effect of colchicine on ischemic heart disease, this study was performed to evaluate the cardioprotective effect of colchicine in PMI following elective PCI. Methods: A randomized clinical trial including a total number of 102 patients undergoing elective PCI was performed. Intervention group (n=51) received 2mg Colchicine(two times in day) plus the standard treatment(aspirin 325 mg, clopidogrel 300 mg, weight-adjusted intravenous heparin with a target activated clotting time 250-350 seconds(, while the control group (n=51) only received the standard treatment. To assess myocardial damage during elective PCI, serum concentrations of CK-MB and cTnI were measured before, 8 hours and 24 hours after elective PCI. Result: There were no significant differences in cTnI levels at 8 hours (p=0/387) and 24 hours (p=0.0/822) after elective PCI between Colchicine and the control group. Conclusion: This study did not support the potential cardioprotective effect of pre-treatment with Colchicine in PMI in patients undergoing elective PCI. However, a non-significant trend toward the potential benefit of Colchicine was observed in the present study. Large randomized clinical trials are still needed to investigate the role of colchicine on PMI following elective PCI.